Reportedly, a large number of microRNAs (miRNAs) play an important role in inflammatory lung diseases such as asthma, idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), and pulmonary arterial hypertension (PAH). Sevoflurane is routinely used to various patients, and its safety has been confirmed by clinical outcomes; however, its effects to lungs at the miRNA level have not been elucidated. In our previous genomic studies, we showed that sevoflurane anesthesia affected the expression of many genes and mRNAs in rat lungs. In this study, we comprehensively investigated changes in miRNA expression caused by sevoflurane anesthesia (2.0% and 4.0%). Sevoflurane anesthesia resulted in apparent changes in miRNA expression in rat lungs, and the pattern of 2.0% sevoflurane-induced changes in miRNA expression was similar to that of 4.0% sevoflurane. Some of the differentially expressed miRNAs are known to be involved in asthma, IPF, and PAH. Especially, miR-146a, the most up-regulated miRNA, is known to attenuate the toxic effects associated with LPS stimulation. We showed, for the first time, dynamic changes in miRNA expression caused by sevoflurane anesthesia, and moreover, our results were important to understand the influence of sevoflurane anesthesia on any patients suffered from various lung diseases.
Although anesthesia involves many procedures that may cause severe lung constriction (3, 5, 8, 10, 23) , inhalation anesthesia, such as sevoflurane, is often associated with significant improvements in lung function (7, 13, 15, 20) . For example, Suter et al. have recently shown that, in an in vitro model of endotoxin-induced lung injury, production of inflammatory proteins is attenuated in alveolar epithelial cells following sevoflurane preconditioning (30) . Post-conditioning with sevoflurane attenuates lung damage and preserves lung function in in vivo and in vitro models of acute respiratory distress syndrome (ARDS) (29, 32) . Additionally, Conno et al. showed that patients who received sevoflurane while undergoing one-lung ventilation for thoracic surgery experienced a significant reduction in inflammatory mediators and significantly better clinical outcomes than patients who received propofol (2) . In recent years, the presence of non-coding RNAs, termed microRNAs (miRNAs), that consist of about 20 bases has become a focus of attention. It is now known that miRNAs bind to the 3'-untranslated regions of target mRNA. Binding of miRNA to a mRNA target that has partially complementary sequences inhibits translation of that mRNA, and binding to a target that has perfectly complementary mRNA leads to the degradation of the mRNA (1, 6, 9, 12) . Reportedly, a large number of these small RNAs are associated with inflammatory lung diseases and pulmonary vascular diseases, such as cystic fibrosis, = 0.4) and allowed to breathe spontaneously; their body temperatures were maintained at 37°C with a heat lamp. Rats in either sevoflurane group were anesthetized in the cage by inhalation of 2.0% or 4.0% sevoflurane, and each rat was killed after 6 h of anesthesia. Each rat in the control group was sacrificed 6 h after having been placed in individual plastic cages identical to those used for the sevoflurane-treated groups and supplied with only the airoxygen mixture. The lungs were harvested from each rat immediately after the rat was sacrificed. The tissue samples were washed twice with cold PBS to clear any blood, and stored at −20°C in RNAlater ® solution (Applied Biosystems, Foster City, CA, USA). After storage for 1 day, the RNAlater solution was rapidly separated from the samples by centrifugation (10,000 × g, +4°C, 5 min). Total RNA was extracted using a mirVana miR Isolation kit (Applied Biosystems). RNA quantity and quality were assessed with NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA). Any RNA sample with an A260/280 nm reading ≥1.8 was qualified for quantitative analysis; then, the total RNA samples containing miRNA were used for quantitative reverse-transcription PCR (qRT-PCR).
Physiological parameters. Physiological variables were measured from using three other groups of rats (2.0%, 4.0% and control group, n = 7 for each, Table 1) that had been treated exactly as had the three groups (2 sevoflurane groups and 1 control group) from which we took the lung samples. For each of these rats, a catheter was inserted into the tail vein without anesthesia, and LR solution was infused continuously at 10 mL/kg/h. During the experiment, each rat was placed into a plastic cage (45 × 32 × 23 cm) supplied with an air-oxygen mixture (fraction of inspired oxygen [FiO 2 ] = 0.4) and allowed to breathe spontaneously; their body temperatures were maintained at 37°C using a heat lamp. In order to draw blood samples for measuring arterial PO 2 , arterial PCO 2 , arterial blood pH, heart rate, and arterial blood pressure, each rat was anesthesitized with 2.0% sevoflurane, and we cannulated the left femoral artery. After full recovery from anesthesia, in the sevoflurane group, 2.0% or 4.0% sevoflurane anesthesia was maintained for an additional 6 h. The control blood samples were taken after full recovery from the initial 2.0% sevoflurane anesthesia treatment. The sevoflurane groups had blood samples taken at 3 and 6 h after the induction of anesthesia. chronic obstructive pulmonary disease (COPD), asthma, ARDS, idiopathic pulmonary fibrosis (IPF), lung cancer, and pulmonary arterial hypertension (PAH) (14, 25, 26) . Sevoflurane is routinely used as a surgical procedure, and its safety has been confirmed by clinical outcomes; however, its effects at the miRNA level have not been elucidated. If sevoflurane anesthesia affects expression of miRNAs in the lung, we may need to take into consideration the influence of sevoflurane anesthesia on any patients that are affected with inflammatory lung diseases (such as asthma, ARDS, and IPF), lung cancer, and PAH. Therefore, it is very important to investigate changes in miRNA expression caused by sevoflurane anesthesia.
As far as we know, no published studies have addressed the relationship between sevoflurane anesthesia and expression of miRNAs in lungs. In our previous genomic studies, we showed that sevoflurane anesthesia affected the expression of many genes and mRNAs in rat lungs (27, 31) ; therefore, we hypothesized that sevoflurane anesthesia also influences miRNA expression in the lung. Using TaqMan low-density arrays (TLDAs), we investigated sevoflurane-dependent changes in miRNA expression in rat lungs. We also analyzed changes in miRNA expression caused by a difference in the concentration of sevoflurane anesthesia (2.0% versus 4.0%).
MATERIALS AND METHODS
Sample preparation. The experimental procedures were approved by the institutional Committee on Laboratory Animals of Nippon Medical School (approval number: 23-069), and were performed within the guidelines of the International Association for the Study of Pain (24) . Seven-week-old male Wistar rats (Saitama Experimental Animals Supply, Saitama, Japan) weighing 250 ± 10 g were randomly assigned to one of three groups. Rats in the first group were given 4.0% sevoflurane anesthesia for 6 h (4.0% sevoflurane group, n = 7), those in the second group were given 2.0% sevoflurane for 6 h (2.0% sevoflurane group, n = 7), and those in the third group received no anesthesia (control group, n = 7). For all rats, a catheter was inserted into the tail vein without anesthesia, and lactated Ringer's (LR) solution was infused continuously at 1 mL/100 mg/h. During the experiment, each rat was placed into a plastic cage (45 × 32 × 23 cm) supplied with an airoxygen mixture (fraction of inspired oxygen [FiO 2 ]
To verify the accuracy of our TLDA data, we performed separate standard qRT-PCR experiments for individual miRNAs using single Taqman microRNA assays (Applied Biosystems) (28) . Single TaqMan assays rely on the same technology as TLDA. Normalization was performed with U6, the same internal control as TLDA. Reactions were run in triplicate in 96-well plates on a 7900 HT Real-Time PCR System.
Statistical analyses.
Values are expressed as mean ± standard deviation. Tukey's tests were used to compare the vital signs and miRNA expression levels in the 2.0%, 4.0%, and control groups, and values of P < 0.05 were considered significant. Two-tailed paired t-tests were used to compare the miRNA expression data from TLDA analysis with those from the single qRT-PCR analysis; the significance level for these tests was set at P < 0.05. All statistical procedures were performed by Kyplot 5.0 (KyensLab Incorporated).
RESULTS
All rats survived until sacrifice, and data from all animals were used.
Physiological data
We investigated the effects of sevoflurane anesthesia on the physiological parameters in three groups of rats. The mean arterial pressure in either of the sevoflurane groups was lower than that in the control group over the course of the 6-h treatment (Table 1). There was no significant differences in mean arterial pressure between the 2.0% sevoflurane group and the control group at 3 h or 6 h, or between the 4.0% sevoflurane group and the control group at 3 h (P = 0.49, 0.43, 0.092, respectively); however, mean arterial pressure was significantly lower in the 4.0% sevoflurane group than in the control group at 6 h (P = 0.0051).
miRNA screening test and standard qRT-PCR of individual miRNAs. The miRNA expression profiles were analyzed using TLDA Rodent MicroRNA cards v.3 A and B (Applied Biosystems). Each card contains 375 preloaded rodent miRNA targets, all catalogued in the miRBase database, and three endogenous controls: 1) Mamm U6, 2) U87, and 3) Y1. All procedures were performed as described in a previous report (33) . Briefly, TLDAs were performed by a two-step process. During the first step, 800 ng total RNA per sample was reverse-transcribed using Megaplex RT primer Pool A and B, up to 381 stem-looped primers per pool, and a TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). In the second step, the resulting complementary DNA was diluted, mixed with TaqMan Universal PCR master mix (Applied Biosystems) and deionized distilled water (Wako, Tokyo, Japan), and loaded into one of the eight fill ports on a TLDA microfluidic cards. The cards were briefly centrifuged for 1 min at 1600 × g to distribute samples to the multiple wells connected to the fill ports and then sealed to prevent well-to-well contamination. Finally, the cards were processed and analyzed using a 7900 HT Real-Time PCR System (Applied Biosystems). The data analysis was performed using DataAssist software v2.0 (Applied Biosystems). The data were represented as the threshold cycle (CT) values, where CT represents a unitless value defined as the fractional cycle number at which the sample fluorescence signal passes a fixed threshold above baseline. For each miRNA, the expression level was calculated by the comparative CT method (ΔΔCT), and was further analyzed by comparing the fold change to basal levels in the control samples. Graphic displays were visualized as heat-map results of hierarchical clustering. Distances between samples and assays were calculated for hierarchical clustering based on ΔCT values using Euclidean Distance. For all other physiological parameters, there were no statically significant differences between any of the groups. Our data showed no evidence of hypoxia, hypo/hypercapnia, or hypothermia in any of the three groups (Table 1) .
miRNA screening test: TLDA
The results of the TLDA analysis are presented in Table 2 (n = 7 for each group). Of 750 miRNAs analyzed, expression of 376 miRNAs was related to were converted into a heat map to understand the similarity of the miRNA expression pattern of each sample (Fig. 1) . Each column represents a sample, and, each row shows miRNA. The dendrograms of clustering analysis for miRNAs and samples are displayed on the top and the right respectively. The right dendrogram separated the expression profiles of control group from sevoflurane anesthesia groups (2.0% and 4.0%). Data from the sevoflurane groups (2.0% and 4.0%) were clearly separated from data from the control group for card A and card B; in contrast, data from the 2.0% sevoflurane and 4.0% sevoflurane groups were mixed.
Single qRT-PCR analysis of representative miRNAs
To validate the TLDA results, we selected five individual differentially expressed miRNAs for single qRT-PCR analysis. We selected the most up-regulated and down-regulated miRNAs, miR-146a and miR-21, respectively in the sevoflurane groups based on the TLDA data. We selected let-7d, miR-26a, and -26b to represent genes for which sevoflurane induced moderate differences in expression. The single qRT-PCR results of these five miRNAs (control vs 2.0% sevoflurane and control vs 4.0% sevoflurane) were significantly different (Table 3) . Furthermore, fold changes of each of these miRNAs as determined using TLDA correlated well with those determined using single qRT-PCR analyses; moreover, there were no significant differences between the results from the TLDA analysis and the single qRT-PCR analysis (Table 4A and 4B).
DISCUSSION
The main finding of this study was that sevoflurane anesthesia influenced miRNA expression in rat lungs. Cluster analyses of data from the TLDA yielded a separation of the sevoflurane anesthesia groups (2.0% and 4.0%) from the control group, whereas data from the 2.0% sevoflurane and 4.0% sevoflurane groups were mixed. These findings indicated that sevoflurane anesthesia caused apparent changes in miRNA expression, and the pattern of 2.0% sevoflurane-induced changes in miRNA expression was similar to that of 4.0% sevoflurane.
Though single qRT-PCR assays and TLDA rely on identical amplification technology, single qRT-PCR is a very reliable method for analysis of miRNA expression because the reactions are run in triplicate; in contrast, TLDA reactions are run as singlets. To verify our TLDA data, we performed single qRT-PCR assays using five representative miRNAs that have been studied previously (11, 19) . Hui and coworkers showed that the technical reproducibility of TLDAs was high (intra-sample correlations >0.9, accuracy 92.8%) (11). Mees and co-workers also demonstrated that the miRNA expression validation rate of TLDA is 100% against standard qRT-PCR (19) . For these five representative genes, the qRT-PCR and TLDA results were very similar, and fold changes of the miRNAs by TLDA correlated well with those observed in the single qRT-PCR experiment. These results confirmed that TLDA was as accurate a method as was single qRT-PCR, and our TLDA data were reliable.
In our previous genomic studies, we administered 4.0% or 4.5% sevoflurane for 6 h and showed that sevoflurane anesthesia affected the expression of many genes and mRNAs in rat lungs (27, 31) . Here, the reason we experimented with both 2.0% and 4.0% sevoflurane is that inhalation of 4.0% sevoflurane affected circulation (Table 1) , and as a result, hypotension, rather than the drug itself, could have affected miRNA expression. In the 2.0% sevoflurane group, there was no evidence of hypoxia, hypercapnia, hypotension, or hypothermia. Therefore, we concluded that any changes in miRNA expression in the 2.0% sevoflurane group (28 miRNAs) were caused only by the influence of sevoflurane anesthesia itself. Some of the differentially expressed 28 miRNAs are known to be involved in inflammatory lung diseases and PAH. For example, miR-126, -21, and -26a are important in asthma (17, 18, 21) ; let7d, miR-21, -155, and -29 are important in IPF (26); and miR-146a, -155, -21, -25, and -26a are important in PAH (14) . Here, we found that expression of each of these miRNA was significantly changed by sevoflurane anesthesia; therefore, sevoflurane anesthesia may affect lung diseases such as asthma, IPF, and PAH. Although administration of sevoflurane anesthesia is often associated with significant improvements in lung function (7, 13, 15, 20) , the changes in miR146a expression, most up-regulated miRNA in our TLDA data, may play an important role in regulating the mechanisms mediating the anti-inflammatory effects on ARDS. Lipopolysaccharide (LPS) is the principal component of the outer membrane of gram-negative bacteria. LPS-induced toll-like receptor 4 (TLR4) signal transduction activates NF-κB, leading to the production of pro-inflammatory cytokines such as TNF-α and IL-6 (16) . The change in miR-146a expression is reportedly important in the TLR4 signaling pathway (22) , and our data indicated that sevoflurane anesthesia resulted in significant es in expression of miRNAs known to be involved in PAH and inflammatory lung diseases. We propose that these results will provide new insights into the actions of sevoflurane in the lung. However, our TLDA data was not satisfactory because it provided only a snapshot of the changes in miRNA expression. Reportedly, changes in miRNA expression that are induced by extrinsic stimuli occur at early stages and continue for a long time (22) . Additionally, miRNAs work to silence their complementary target genes (4), and we did not assess whether the changes in miRNA expression correlated with changes in actual local production of transcriptional factors or downstream markers.
In conclusion, sevoflurane anesthesia affected expression of miRNAs in rat lungs, and moreover, our TLDA results were important to understand the inchanges in expression of this miRNA. The increase in miR-146a expression attenuates the toxic effects associated with LPS stimulation by controlling TLR4 and cytokine signaling through a negative feedback loop that involves downregulation of IL-1 receptorassociated kinase 1 (a recently identified ARDS candidate gene) and TNF receptor-associated factor 6 protein (22) . Our TLDA data showed that miR-146a levels were about 2 times increased in the sevoflurane groups than in the control group, indicating that sevoflurane anesthesia may decrease the toxic effects of LPS by altering miR-146a expression.
The present study showed, for the first time, obvious changes in miRNA expression that were caused by sevoflurane anesthesia and possibly by the effects of an anesthetic, including hypotension. Moreover, sevoflurane anesthesia resulted in chang- Values of Fold Change are expressed as mean ± standard deviation. The significance level was set at P < 0.05, determined by Tukey's tests. Values of Fold Change are expressed as mean ± standard deviation. The significance level was set at P < 0.05, determined by two-tailed paired t-tests. Values of Fold Change are expressed as mean ± standard deviation. The significance level was set at P < 0.05, determined by two-tailed paired t-tests.
fluence of sevoflurane anesthesia on any patients suffered from various lung diseases. In the future, we plan to investigate the time-dependent changes in miRNA expression, and to investigate miRNA expression changes caused by sevoflurane anesthesia in different models such as asthma, ARDS, and PAH.
